To Tell the Truth, the Whole Truth, May Do Patients Harm: The Problem of the Nocebo Effect for Informed Consent

American Journal of Bioethics

Volumn 12, Issue 3, 2012, Pages 22-29

  Wells, Rebecca Erwin ^a   Kaptchuk, Ted J ^b  

^a Brigham and Women's/Faulkner Hospitals   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

decision making; informed consent; professional ethics; professional patient relationship

Indexed keywords

ANTICIPATION; ARTICLE; BENEFICENCE; CLINICAL TRIAL (TOPIC); DECISION MAKING; DOCTOR PATIENT RELATION; DRUG TOXICITY; ETHICS; HUMAN; INFORMED CONSENT; INTERPERSONAL COMMUNICATION; MEDICAL ETHICS; PATERNALISM; PERSONAL AUTONOMY; PUBLIC HEALTH; STANDARD;

ANTICIPATION, PSYCHOLOGICAL; BENEFICENCE; CLINICAL TRIALS AS TOPIC; COMMUNICATION; DECISION MAKING; DRUG TOXICITY; ETHICS, MEDICAL; HUMANS; INFORMED CONSENT; PATERNALISM; PERSONAL AUTONOMY; PHYSICIAN-PATIENT RELATIONS; PUBLIC HEALTH; TRUTH DISCLOSURE;

EID: 84859486530     PISSN: 15265161     EISSN: 15360075     Source Type: Journal    
DOI: 10.1080/15265161.2011.652798     Document Type: Article

References (48)

1. Ainslie, G. 2001. Breakdown of will, Cambridge: Cambridge University Press.
2. Amanzio, M., Corazzini, L. L., Vase, L. and Benedetti, F. 2009. A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain, 146(3): 261-269.
3. Barilan, Y. M. 2010. Informed consent: Between waiver and excellence in responsible deliberation. Medicine, Health Care and Philosophy, 13: 89-95.
4. Barsky, A. J. and Borus, J. F. 1999. Functional somatic syndromes. Annals of Internal Medicine, 130(11): 910-921.
5. Barsky, A. J., Saintfort, R., Rogers, M. P. and Borus, J. F. 2002. Nonspecific medication side effects and the nocebo phenomenon. Journal of American Medical Association, 287(5): 622-627.
6. Benedetti, F., Amanzio, M. and Maggi, G. 1995. Potentiation of placebo analgesia by proglumide. Lancet, 346(8984): 1231
7. Benedetti, F., Amanzio, M., Vighetti, S. and Asteggiano, G. 2006. The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect. Journal of Neuroscience, 26(46): 12014-12022.
8. Benedetti, F., Lanotte, M., Lopiano, L. and Colloca, L. 2007. When words are painful: Unraveling the mechanisms of the nocebo effect. Neuroscience, 147(2): 260-271.
9. Davies, S. J., Jackson, P. R., Ramsay, L. E. and Ghahramani, P. 2003. Drug intolerance due to nonspecific adverse effects related to psychiatric morbidity in hypertensive patients. Archives of Internal Medicine, 163(5): 592-600.
10. de la Cruz, M, Hui, D., Parsons, H. A. and Bruera, E. 2010. Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer. Cancer, 116(3): 766-774.
11. Epstein, R. M., Alper, B. S. and Quill, T. E. 2004. Communicating evidence for participatory decision making. Journal of American Medical Association, 291(19): 2359-2366.
12. Faasse, K., Cundy, T. and Petrie, K. J. 2009. Medicine and the media. Thyroxine: Anatomy of a health scare. British Medical Journal, 339: b5613
13. Faden, R. R., Becker, C., Lewis, C., Freeman, J. and Faden, A. I. 1981. Disclosure of information to patients in medical care. Medical Care, 19(7): 718-733.
14. Geers, A. L., Wellman, J. A., Fowler, S. L., Rasinski, H. M. and Helfer, S. G. 2010. Placebo expectations and the detection of somatic information. Journal of Behavioral Medicine, 34: 208-217.
15. General Medical Council (Great Britain). 2008. Consent: Patients and doctors making decisions together London
16. Gillon, R. 2003. Ethics needs principles-Four can encompass the rest-And respect for autonomy should be "first among equals. Journal of Medical Ethics, 29(5): 307-312.
17. Grimes, D. A. and Schulz, K. F. 2011. Nonspecific side effects of oral contraceptives: Nocebo or noise?. Contraception, 83(1): 5-9.
18. Gurwitz, J. H., Field, T. S., Harrold, L. R., Rothschild, J., Debellis, K., Seger, A. C., Cadoret, C., Fish, L. S., Garber, L., Kelleher, M. and Bates, D. W. 2003. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. Journal of American Medical Association, 289(9): 1107-1116.
19. Hahn, R. A. 1997. The nocebo phenomenon: Concept, evidence, and implications for public health. Preventive Medicine, 26(5 pt 1): 607-611.
20. Johnson, J. A. and Bootman, J. L. 1995. Drug-related morbidity and mortality. A cost-of-illness model. Archives of Internal Medicine, 155(18): 1949-1956.
21. Jones, T. F., Craig, A. S., Hoy, D., Gunter, E. W., Ashley, D. L., Barr, D. B., Brock, J. W. and Schaffner, W. 2000. Mass psychogenic illness attributed to toxic exposure at a high school. New England Journal of Medicine, 342(2): 96-100.
22. Kanaan, R., Armstrong, D. and Wessely, S. 2009. Limits to truth-telling: Neurologists' communication in conversion disorder. Patient Education and Counseling, 77(2): 296-301.
23. Kaptchuk, T. J., Stason, W. B. and Davis, R. B., et al. 2006. Sham device v inert pill: Randomised controlled trial of two placebo treatments. British Medical Journal, 332(7538): 391-397.
24. Kong, J., Gollub, R. L., Polich, G., Kirsch, I., Laviolette, P., Vangel, M., Rosen, B. and Kaptchuk, T. J. 2008. A functional magnetic resonance imaging study on the neural mechanisms of hyperalgesic nocebo effect. Journal of Neuroscience, 28(49): 13354-13362.
25. Lang, E. V., Hatsiopoulou, O. and Koch, T., et al. 2005. Can words hurt? Patient-provider interactions during invasive procedures. Pain, 114(1-2): 303-309.
26. Manson, N. C. and O'Neill, O. 2007. Rethinking informed consent in bioethics, Cambridge: Cambridge University Press.
27. McNeil, B. J., Pauker, S. G., Sox, H. C. Jr. and Tversky, A. 1982. On the elicitation of preferences for alternative therapies. New England Journal of Medicine, 306(21): 1259-1262.
28. Miller, F. G. and Colloca, L. 2011. The placebo phenomenon and medical ethics: Rethinking the relationship between informed consent and risk-benefit assessment. Theoretical Medicine and Bioethics, 32: 229-243.
29. Mitsikostas, D. D., Mantonakis, L. I. and Chalarakis, N. G. 2011. Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches. Cephalalgia, 31(5): 550-561.
30. Mondaini, N., Gontero, P.Giubilei, G. 2007. Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon?. Journal of Sexual Medicine, 4(6): 1708-1712.
31. Montgomery, K. 2006. How doctors think: Clinical judgment and the practice of medicine, New York, NY: Oxford University Press.
32. Myers, M. G., Cairns, J. A. and Singer, J. 1987. The consent form as a possible cause of side effects. Clinical Pharmacology and Therapeutics, 42(3): 250-253.
33. Nestoriuc, Y., Orav, E. J., Liang, M. H., Horne, R. and Barsky, A. J. 2010. Prediction of nonspecific side effects in rheumatoid arthritis patients by beliefs about medicines. Arthritis Care & Research, 62(6): 791-799.
34. O'Connor, A. M., Pennie, R. A. and Dales, R. E. 1996. Framing effects on expectations, decisions, and side effects experienced: The case of influenza immunization. Journal of Clinical Epidemiology, 49(11): 1271-1276.
35. Olshansky, B. 2007. Placebo and nocebo in cardiovascular health: Implications for healthcare, research, and the doctor-patient relationship. Journal of the American College of Cardiology, 49(4): 415-421.
36. Pennebaker, J. W. and Skelton, J. A. 1981. Selective monitoring of physical sensations. Journal of Personality and Social Psychology, 41(2): 213-223.
37. Psaty, B. M., Koepsell, T. D., Wagner, E. H., LoGerfo, J. P. and Inui, T. S. 1990. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. Journal of American Medical Association, 263(12): 1653-1657.
38. Rastam, L., Selander, S. and Troein, M. 1992. Communication in care: A structural framework. European Journal of Public Health, 2: 123-127.
39. Reidenberg, M. M. and Lowenthal, D. T. 1968. Adverse nondrug reactions. New England Journal of Medicine, 279(13): 678-679.
40. Rief, W., Avorn, J. and Barsky, A. J. 2006. Medication-attributed adverse effects in placebo groups: Implications for assessment of adverse effects. Archives of Internal Medicine, 166(2): 155-160.
41. Rief, W., Barsky, A. J., Glombiewski, J. A., Nestoriuc, Y., Glaesmer, H. and Braehler, E. 2011. Assessing general side effects in clinical trials: Reference data from the general population. Pharmacoepidemiology and Drug Safety, 20(4): 405-415.
42. Rief, W., Nestoriuc, Y.von Lilienfeld-Toal, A. 2009. Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: A systematic review and meta-analysis. Drug Safety, 32(11): 1041-1056.
43. Schwab, A. P. 2006. Formal and effective autonomy in healthcare. Journal of Medical Ethics, 32(10): 575-579.
44. Scott, D. J., Stohler, C. S., Egnatuk, C. M., Wang, H., Koeppe, R. A. and Zubieta, J. K. 2008. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Archives of General Psychiatry, 65(2): 220-231.
45. Silvestri, A., Galetta, P., Cerquetani, E., Marazzi, G., Patrizi, R., Fini, M. and Rosano, G. M. 2003. Report of erectile dysfunction after therapy with beta-blockers is related to patient knowledge of side effects and is reversed by placebo. European Heart Journal, 24(21): 1928-1932.
46. Spiegel, H. 1997. Nocebo: The power of suggestibility. Preventive Medicine, 26(5 pt 1): 616-621.
47. Stern, R. H. 2008. Nocebo responses to antihypertensive medications. Journal of Clinical Hypertension, 10(9): 723-725.
48. Varelmann, D., Pancaro, C., Cappiello, E. C. and Camann, W. R. 2010. Nocebo-induced hyperalgesia during local anesthetic injection. Anesthesia and Analgesia, 110(3): 868-870.